Emerging Regenerative Medicine Technology Working Group

Charter

The Emerging Regenerative Medicine Technology (ERMT) Working Group aims to evaluate new innovative therapeutic technologies in addressing current challenges and gap in the development of cell and gene therapies through the lens of process development and biomanufacturing.

The committee will review, inform and discuss issues that are critical for translating towards the clinic for accelerated development of safe and effective cell therapies with an initial focus on iPSC and iPSC-derived cells, and later on other technologies such as tissue engineering and gene editing.  

Goals

• Review current challenges and gaps in emerging cell therapy approaches field and inform best practices and methods with proven use
• Discuss emerging manufacturing technologies and their impact on overcoming current bioprocessing bottlenecks
• Coordinate with other ISCT committees to drive consensus and disseminate information though publications and presentations.
  
  

Projects & Objectives

• In progress Whitepaper Engineering iPSCs: Harnessing Gene Editing Tools for Clinical Transformation due for publication Q2 2026.
• Survey: To inform planned landscape analysis on key innovations, and technologies supporting iPSC product development and commercialization. 
• Published White papers:
• Scaling up pluripotent stem cell-based therapies - considerations, current challenges and emerging technologies (2025)
  
• Bioprocessing considerations for generation of iPSCs intended for clinical application (2024)

The 2024 Roster

CGT Catapult

Emmanuelle Cameau
Cytiva

Dominic Clarke
Cryoport Systems

Noushin Dianat
Sartorius Stedim Biotech GmbH

Lonza

Benjamin Fryer 
Pluristyx

QIAGEN

Scott Jones

BioBridge Global 

Stemcell Technologies

Aspen NeuroScience 

Terumo BCT

Bar Makovoz
Cellino Biotech, Inc.

Ana Martini

Akron Biotech

PL BioScience GmhH

Independent